Literature DB >> 19903790

Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?

Andrea P Myers1, Jeffrey A Meyerhardt, Lewis C Cantley.   

Abstract

There is high morbidity associated with local recurrence of rectal cancer. However, the adjuvant therapies given to prevent such recurrences also have significant side effects and associated risks. The ability to select patients with the highest risk of recurrence and greatest therapeutic response will improve rectal cancer care.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19903790      PMCID： PMC3400141          DOI： 10.1158/1078-0432.CCR-09-2305

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 2.  NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.

Authors: 
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

3.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

4.  Molecular signatures predict outcomes of breast cancer.

Authors:  Joyce A O'Shaughnessy
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

5.  Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party.

Authors: 
Journal:  Lancet       Date:  1996-12-14       Impact factor: 79.321

6.  PIK3CA mutations predict local recurrences in rectal cancer patients.

Authors:  Youji He; Laura J Van't Veer; Izabela Mikolajewska-Hanclich; Marie-Louise F van Velthuysen; Eliane C M Zeestraten; Iris D Nagtegaal; Cornelis J H van de Velde; Corrie A M Marijnen
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

Review 7.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Authors:  Leonard L Gunderson; Daniel J Sargent; Joel E Tepper; Norman Wolmark; Michael J O'Connell; Mirsada Begovic; Cristine Allmer; Linda Colangelo; Steven R Smalley; Daniel G Haller; James A Martenson; Robert J Mayer; Tyvin A Rich; Jaffer A Ajani; John S MacDonald; Christopher G Willett; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

9.  Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects.

Authors:  G J Frykholm; B Glimelius; L Påhlman
Journal:  Dis Colon Rectum       Date:  1993-06       Impact factor: 4.585

Review 10.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.